Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment

Leqembi's rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and regular brain scans, among others.

Sep 8, 2024 - 22:00

0 7

Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment

Leqembi's rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and regular brain scans, among others.

Tags:

Previous Article

JPMorgan downgrades its opinion on China, but still likes these individual stocks

As consumers trade down to cheaper private label brands, these stocks could head up

admin

admin

This website uses cookies to enhance your browsing experience. By continuing to use this site, you consent to the use of cookies. Please review our Privacy Policy for more information on how we handle your data.